Composition
1 tablet contains:
active ingredient: microcrystalline hydroxyapatite complex MSNAtm (MSN-Caltm) – 1000 mg (mg), vitamin K2 (menaquinone-7) – 25 μg (μg), vitamin D3 (cholecalciferol) – 12.5 μg (μg) (500 IU (IU));
excipients: fillers: microcrystalline cellulose, CompactCel® (hydroxypropylcellulose, sodium carboxymethylcellulose), anti-caking agent: magnesium stearate.
MSN-Caltm - includes 250 mg (mg) of proteins (collagen type I and non-collagen peptides including insulin-like growth factor type I and II (IGF1 - 0.285 μg (µg), IGF2 - 0.17 μg (µg)), transforming growth factor beta (TGF-β - 0.0275 μg (µg)), osteocalcin - 604 μg (µg)) and 670 mg (mg) of calcium hydroxyapatite (including 250 mg (mg) of calcium, 125 mg (mg) of phosphorus, 4 mg (mg) of magnesium, 64 μg (µg) of zinc, 3.9 μg (µg) of iron and 1.4 μg (µg) of boron)*
*typical average content of components.
GMO-free
Properties
OSTEOPRO® is a calcium-phosphorus complex with vitamins D3 and K2, containing a special compound - microcrystalline hydroxyapatite complex MSNAtm (MSN-Caltm), also known as ossein-hydroxyapatite complex, and is an active regulator of calcium-phosphorus metabolism.
The complex contains an organic and mineral component.
The mineral component (calcium hydroxyapatite) contains calcium, phosphorus and some other macro- and microelements (magnesium, zinc, iron, boron). Calcium is contained in the form of hydroxyapatite, which contributes to its more complete absorption from the gastrointestinal tract. Phosphorus, which participates in the crystallization of hydroxyapatite, promotes the fixation of calcium in the bones and inhibits its excretion by the kidneys. Magnesium participates in the regulation of bone mineralization, contributes to its flexibility, strength and improvement of reparative potential. Zinc is a cofactor of more than 300 enzymes that take part in various metabolic processes, including bone tissue. Iron takes part in the metabolism of collagen, from which, among other things, trabeculae of bone tissue are built. Boron has a pronounced effect on the growth processes of bone tissue and cartilage cells, increasing the level of osteogenesis proteins - osteocalcin, type 1 collagen, bone morphogenesis proteins 4, 6 and 7, as well as osteopontin, bone sialoprotein (BSP gene), and Runx2 protein.
The organic component (known as ossein) is represented by proteins and peptides (growth factors, osteocalcin, collagen, etc.). Growth factors: insulin-like growth factors 1 and 2 (IGF1, IGF2), transforming growth factor beta (TGF-β).
IGF1 and IGF2 are able to influence the synthesis of collagen and other bone proteins, as well as activate the proliferation and maturation of osteoblasts. There is evidence of their influence on the formation of cartilage tissue and fracture healing in the experiment.
TGF-β has a significant effect on bone metabolism, in particular the proliferation of the cell pool and the main substance of bone tissue. One of the key growth factors that takes an active part in all phases of the reparative process in a fracture.
OSTEOPRO® also contains vitamins D3 (cholecalciferol) and K2 (menaquinone-7 (MK-7)).
Vitamin D3 (cholecalciferol) contributes to the normal absorption/assimilation of calcium and phosphorus, promotes calcium absorption in the duodenum and proximal small intestine. In the intestine, vitamin D3 enhances calcium absorption, with the participation of calcium-binding proteins (calbindins) transports calcium through the intestinal wall into the blood and promotes calcium absorption by bone tissue. Vitamin D3 contributes to increased calcium reabsorption in the kidneys. On the part of the bone system, active metabolites of vitamin D regulate phosphorus-calcium metabolism. Under the influence of active forms of vitamin D in osteoblasts, the synthesis of transforming growth factor increases, the number of receptors for insulin-like growth factor increases, the synthesis of type 1 collagen and matrix proteins (osteocalcin and osteopontin) increases, which are necessary for mineralization, functioning and metabolism of bone tissue.
Vitamin K2 (menaquinone-7 (MK-7)) stimulates the production of special proteins osteocalcin and matrix GLA-protein, which are necessary for the binding of calcium and hydroxyapatite to collagen and contribute to the organization of the extracellular matrix of bone. Vitamin K2 reduces bone resorption, promotes collagen synthesis in osteoblasts and reduces the risk of vertebral fractures.
Vitamins D and K contribute to the maintenance of normal bone health and bone mineralization. They have a synergistic effect, so they should be used in combination to prevent fractures in both healthy individuals and patients with osteoporosis.
Recommendations for use
OSTEOPRO® is an additional source of calcium, phosphorus, proteins (collagen, growth factors, osteocalcin) and vitamins D3 and K2. It is recommended for the regulation of calcium-phosphorus metabolism in case of calcium deficiency in the body, osteoporosis and to improve bone growth in case of fractures.
Method of application
In other conditions for the purpose of regulating calcium-phosphorus metabolism, with calcium deficiency in the body, osteoporosis: adults should take 2-4 tablets per day (in 2 doses), washed down with a small amount of drinking water, preferably during meals. To facilitate swallowing, the tablets can be chewed. On the recommendation of a doctor, the recommended daily dose may be increased. The course of use is determined by the doctor individually. The minimum recommended course of use is 1 month. Before use, it is recommended to consult a doctor.
Reservation
Do not exceed the recommended daily dose. OSTEOPRO® should not be used as a substitute for a balanced diet. It is important to follow the rules of a varied, balanced diet and a healthy lifestyle.
Contraindication
Individual sensitivity to any of the components, hypercalcemia, hypercalciuria, urolithiasis, tissue calcification, severe renal dysfunction, hyperproliferative processes, vitamin D hypervitaminosis.
Release form
Tablets weighing 1.5 g ± 7.5%, 30 or 60 tablets in a jar packed in a cardboard box.
Expiration date
Indicated on the packaging.
Storage conditions
Store in the original packaging at a temperature of 4°C to 25°C in a dry place, protected from light and out of the reach of children.
Producer
Dr. Gustav Klein GmbH & Co. KG, Germany, Steinenfeld 3, 77736 Zell am Harmersbach; tel.: +49 783563550
Developer of MCHA™ (MCH-Cal™) manufacturing technology and supplier of active ingredients: Waitaki Biosciences a division of PharmaZen Limited, 320 Port Hills Rd, Hillsborough 8022, Christchurch, New Zealand.
